MCID: SQM006
MIFTS: 58

Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 77 54 38 30 6 15 17 74
Carcinoma, Squamous Cell 77 54 45
Epidermoid Carcinoma 12 77 54
Squamous Cell Cancer 12 56 15
Squamous Cell Carcinoma of the Skin 6
Squamous Cell Carcinoma - Category 74
Malignant Squamous Cell Neoplasm 74
Squamous Cell Carcinoma of Skin 74
Malignant Squamous Cell Tumor 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 54
Neoplasms, Squamous Cell 45
Carcinoma Squamous Cell 56
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
KEGG 38 H00040
NCIt 51 C2929
SNOMED-CT 69 28899001

Summaries for Squamous Cell Carcinoma

NIH Rare Diseases : 54 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable.

MalaCards based summary : Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and lung squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioblastoma Multiforme and Senescence and Autophagy in Cancer. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and lymph node.

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

Wikipedia : 77 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1095)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 34.9 BRAF C5orf66-AS1 H19 HOTAIR HRAS MIR205
2 lung squamous cell carcinoma 34.7 BRAF CCAT2 HRAS SOX2-OT TP53 TUG1
3 tongue squamous cell carcinoma 34.6 LINC01503 MALAT1 TP53 UCA1
4 bladder squamous cell carcinoma 34.6 BRAF TP53
5 oral squamous cell carcinoma 34.5 CCAT2 H19 HOTAIR MALAT1 TUG1 UCA1
6 vulva squamous cell carcinoma 34.4 MALAT1 TP53
7 laryngeal squamous cell carcinoma 34.4 CDKN2B-AS1 H19 HOTAIR MALAT1 TP53
8 esophagus squamous cell carcinoma 34.3 HOTAIR LINC01233
9 esophageal cancer 33.6 C5orf66-AS1 CASC9 CDKN2B-AS1 H19 HOTAIR HRAS
10 nasopharyngeal carcinoma 33.5 CASC9 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
11 adenocarcinoma 33.3 BRAF H19 HRAS MALAT1 TP53
12 lung cancer 32.2 BRAF CASC9 CCAT2 CDKN2B-AS1 DDR2 H19
13 prostate cancer 32.1 CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
14 bladder cancer 32.0 C5orf66-AS1 CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS
15 lung cancer susceptibility 3 31.6 BRAF H19 HOTAIR HRAS MALAT1 TP53
16 gastric adenocarcinoma 31.4 BRAF H19 HOTAIR HRAS TP53
17 leukemia, chronic lymphocytic 2 31.4 BRAF HRAS TP53
18 small cell cancer of the lung 31.3 CCAT2 HOTAIR MALAT1 TP53 TUG1
19 transitional cell carcinoma 31.3 BRAF HRAS TP53
20 thyroid cancer, nonmedullary, 1 31.2 BRAF H19 HOTAIR MALAT1
21 melanoma 31.2 BRAF CDKN2B-AS1 H19 HOTAIR MALAT1 MIR205
22 thyroid cancer 31.1 BRAF CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
23 cervical cancer 30.9 CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
24 gastric cardia adenocarcinoma 30.9 C5orf66-AS1 H19 HOTAIR
25 suppression of tumorigenicity 12 30.9 BRAF HRAS TP53
26 colorectal adenocarcinoma 30.8 BRAF HRAS TP53
27 mature teratoma 30.7 BRAF TP53
28 intrahepatic cholangiocarcinoma 30.7 CCAT2 TP53 TUG1
29 large intestine cancer 30.6 BRAF CCAT2 HRAS TP53
30 leukemia, chronic myeloid 30.5 H19 HOTAIR HRAS UCA1
31 endometrial cancer 30.4 BRAF H19 HOTAIR HRAS TP53 TUG1
32 bladder urothelial carcinoma 30.4 BRAF HOTAIR HRAS MALAT1 TP53 TUG1
33 breast cancer 30.3 BRAF CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS
34 b-cell lymphomas 30.3 HOTAIR MALAT1 TP53 TUG1
35 renal cell carcinoma, nonpapillary 30.3 H19 HOTAIR MALAT1 TUG1 UCA1
36 cholangiocarcinoma 30.2 BRAF CCAT2 H19 MALAT1 SOX2-OT SPRY4-IT1
37 hepatocellular carcinoma 30.2 CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
38 glioblastoma 30.2 BRAF H19 HOTAIR HRAS MALAT1 TP53
39 pituitary adenoma 30.2 CCAT2 H19 HOTAIR MALAT1
40 myeloma, multiple 30.1 BRAF H19 HOTAIR HRAS MALAT1 TP53
41 glioma 30.0 BRAF CCAT2 CDKN2B-AS1 H19 HOTAIR MALAT1
42 gastric cancer 30.0 CASC9 CCAT2 CDKN2B-AS1 H19 HOTAIR MALAT1
43 osteogenic sarcoma 29.9 CCAT2 CDKN2B-AS1 H19 HOTAIR MALAT1 SOX2-OT
44 colorectal cancer 29.9 BRAF CCAT2 CDKN2B-AS1 H19 HOTAIR HRAS
45 ovarian cancer 29.7 BRAF CCAT2 CDKN2B-AS1 H19 HOTAIR MALAT1
46 pancreatic cancer 29.7 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1 MIR205
47 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.7
48 gastric squamous cell carcinoma 12.7
49 basaloid squamous cell carcinoma 12.6
50 rectum squamous cell carcinoma 12.6

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

Drugs & Therapeutics for Squamous Cell Carcinoma

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
3
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
5
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
6
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
7
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
8
Titanium dioxide Approved Phase 4 13463-67-7
9
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
10
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
13
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 184475-35-2 123631
14
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 95734-82-0
15
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
16
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
17
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
18
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
20
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
21
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112887-68-0 104758
22
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Cevimeline Approved Phase 4,Phase 3 107233-08-9 25137844 83898
24
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
25
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
27
Morphine Approved, Investigational Phase 4 57-27-2 5288826
28
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
29
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
30
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1 104987-11-3 6473866 445643 439492
31
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
32
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
33
Acitretin Approved Phase 4,Phase 2,Not Applicable 55079-83-9, 69427-46-9 6437841
34
Azathioprine Approved Phase 4 446-86-6 2265
35
Mycophenolic acid Approved Phase 4 24280-93-1 446541
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
37
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 60-18-4 6057
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
39 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Endostatins Phase 4,Phase 3,Phase 2,Phase 1 71581480
41 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Endostar protein Phase 4,Phase 2
43 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2413)
# Name Status NCT ID Phase Drugs
1 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
2 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
5 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
6 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
7 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
8 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
9 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
10 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
11 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
12 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
13 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
14 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
15 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Completed NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
16 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
17 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
18 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
19 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
20 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
21 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
22 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
23 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
24 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
25 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
26 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
27 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
28 Apatinib for Advanced Lung Squmamous Carcinoma Not yet recruiting NCT03725423 Phase 4 Apatinib
29 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease Not yet recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
32 Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease Terminated NCT00472706 Phase 4
33 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
34 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
35 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
36 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
37 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
38 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
39 Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Unknown status NCT02485548 Phase 3 Raltitrexed;5-fluorouracil;Cisplatin
40 Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC Unknown status NCT01874171 Phase 3 Cisplatin;Cetuximab
41 Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
42 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
43 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
44 Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
45 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
46 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
47 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
48 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
49 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
50 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 30

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

42
Skin, Tongue, Lymph Node, Cervix, T Cells, Endothelial, Lung

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 19482)
# Title Authors Year
1
Actinic cheilitis and lip squamous cell carcinoma: Literature review and new data from Brazil. ( 30697396 )
2019
2
From actinic keratosis to squamous cell carcinoma - answers to some open questions. ( 30933346 )
2019
3
T-Cadherin Expression in Actinic Keratosis Transforming to Invasive Squamous Cell Carcinoma. ( 31049318 )
2019
4
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma. ( 31075867 )
2019
5
Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study. ( 30632206 )
2019
6
Is there really no difference of mediastinal lymph node metastasis pattern between esophageal adenocarcinoma and squamous cell carcinoma? ( 31069375 )
2019
7
Reply to 'Is there really no difference of mediastinal lymph node metastasis pattern between esophageal adenocarcinoma and squamous cell carcinoma?' ( 31069377 )
2019
8
Large single cutaneous metastasis of colon adenocarcinoma mimicking a squamous cell carcinoma of the skin: A case report. ( 30870738 )
2019
9
Transformation of adenocarcinoma of prostate to squamous cell carcinoma following hormonal treatment: A case report and review of the literature. ( 30805072 )
2019
10
Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction. ( 30791046 )
2019
11
A Comparative Texture Analysis Based on NECT and CECT Images to Differentiate Lung Adenocarcinoma from Squamous Cell Carcinoma. ( 30707369 )
2019
12
Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma. ( 30673302 )
2019
13
Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. ( 30642444 )
2019
14
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. ( 30642539 )
2019
15
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. ( 30642554 )
2019
16
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. ( 30503889 )
2019
17
Lung Adenocarcinoma has a Higher Risk of Lymph Node Metastasis than Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. ( 30426188 )
2019
18
Spectral Computed Tomography for the Quantitative Assessment of Patients With Carcinoma of the Gastroesophageal Junction: Initial Differentiation Between a Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma. ( 30371624 )
2019
19
Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. ( 30317601 )
2019
20
Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma. ( 30168595 )
2019
21
A new surgical procedure for synchronous esophageal squamous cell carcinoma and gastric adenocarcinoma: Case report: three cases reports. ( 30817620 )
2019
22
Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. ( 30788163 )
2019
23
The Use of "QUAD Shot" in Anal Canal Squamous Cell Carcinoma: A Case Study With Review of the Literature. ( 30403973 )
2019
24
Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. ( 31032082 )
2019
25
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
26
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )
2019
27
Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. ( 30636052 )
2019
28
The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma. ( 30644029 )
2019
29
Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. ( 30773194 )
2019
30
Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. ( 30788159 )
2019
31
Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. ( 31015125 )
2019
32
Early versus late salvage abdominoperineal resection for anal squamous cell carcinoma: Is there a difference in survival? ( 31055841 )
2019
33
The Management and Prevention of Anal Squamous Cell Carcinoma. ( 31099616 )
2019
34
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab. ( 30859062 )
2019
35
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. ( 31106047 )
2019
36
Basaloid Squamous Cell Carcinoma of Tonsil: an Unusual and Aggressive Variant. ( 30948878 )
2019
37
A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma. ( 30813135 )
2019
38
Basaloid Squamous Cell Carcinoma of the Larynx: A National Cancer Database Analysis. ( 30717636 )
2019
39
Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study. ( 29927480 )
2019
40
Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma. ( 30713015 )
2019
41
Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after Mohs micrographic surgery: a retrospective cohort study. ( 30536656 )
2019
42
Effect of multimedia-based nursing visit on perioperative anxiety in esophageal squamous cell carcinoma patients undergoing video-assisted thoracoscopic surgery. ( 30907130 )
2019
43
High-risk Mucosal Human Papillomavirus Infection in Squamous Cell Carcinoma and Bowen's Disease of the Hand. ( 30653652 )
2019
44
Squamous Cell Carcinoma of the Breast Mimicking Chronic Breast Abscess. ( 31007522 )
2019
45
A rare case of ovarian carcinosarcoma with squamous cell carcinoma. ( 30947745 )
2019
46
Squamous Cell Carcinoma Biomarker Sensing on a Strontium Oxide-Modified Interdigitated Electrode Surface for the Diagnosis of Cervical Cancer. ( 31080815 )
2019
47
Radiomics Analysis of Multiparametric MRI Evaluates the Pathological Features of Cervical Squamous Cell Carcinoma. ( 30230114 )
2019
48
Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. ( 30254211 )
2019
49
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. ( 30353913 )
2019
50
Elevated CTHRC1 expression is an indicator for poor prognosis and lymph node metastasis in cervical squamous cell carcinoma. ( 30381261 )
2019

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6 (show top 50) (show all 222)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
5 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
6 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
10 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
11 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
12 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
13 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
15 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
17 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
19 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
20 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
21 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
22 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
23 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
25 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
26 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
27 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
28 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
29 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
30 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
31 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh37 Chromosome 6, 31940123: 31940123
32 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh38 Chromosome 6, 31972346: 31972346
33 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 NCBI36 Chromosome 6, 32048102: 32048102
34 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh37 Chromosome 9, 21971017: 21971017
35 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh38 Chromosome 9, 21971018: 21971018
36 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 NCBI36 Chromosome 9, 21961017: 21961017
37 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
38 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
39 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
40 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
41 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
42 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
43 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
44 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
45 TP53 NM_000546.5(TP53): c.745A> T (p.Arg249Trp) single nucleotide variant Uncertain significance rs587782082 GRCh37 Chromosome 17, 7577536: 7577536
46 TP53 NM_000546.5(TP53): c.745A> T (p.Arg249Trp) single nucleotide variant Uncertain significance rs587782082 GRCh38 Chromosome 17, 7674218: 7674218
47 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
48 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh38 Chromosome 17, 7674257: 7674257
49 TP53 NM_000546.5(TP53): c.746G> A (p.Arg249Lys) single nucleotide variant Uncertain significance rs587782329 GRCh37 Chromosome 17, 7577535: 7577535
50 TP53 NM_000546.5(TP53): c.746G> A (p.Arg249Lys) single nucleotide variant Uncertain significance rs587782329 GRCh38 Chromosome 17, 7674217: 7674217

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 1709)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 19:30445497-30445497 0
2 COSM6976115 YES1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1288C>T p.Q430* 18:736811-736811 0
3 COSM6914703 XPO1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.619C>G p.Q207E 2:61498885-61498885 0
4 COSM6957917 TSC2 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1120A>T p.T374S 16:2061871-2061871 0
5 COSM121050 TP63 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.551C>T p.S184L 3:189808498-189808498 0
6 COSM44097 TP53 skin,face,carcinoma,NS c.530C>T p.P177L 17:7675082-7675082 0
7 COSM10660 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
8 COSM43751 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 0
9 COSM45074 TP53 skin,arm,carcinoma,NS c.829T>G p.C277G 17:7673791-7673791 0
10 COSM10705 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 0
11 COSM10701 TP53 skin,ear,carcinoma,squamous cell carcinoma c.824G>T p.C275F 17:7673796-7673796 0
12 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 0
13 COSM44295 TP53 skin,face,carcinoma,NS c.993+1G>A p.? 17:7673534-7673534 0
14 COSM10939 TP53 skin,face,carcinoma,NS c.832C>T p.P278S 17:7673788-7673788 0
15 COSM43544 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 0
16 COSM10656 TP53 skin,arm,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
17 COSM44326 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 0
18 COSM10662 TP53 skin,face,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
19 COSM45774 TP53 skin,arm,carcinoma,NS c.899C>G p.P300R 17:7673721-7673721 0
20 COSM11449 TP53 skin,face,carcinoma,NS c.388C>T p.L130F 17:7675224-7675224 0
21 COSM44068 TP53 skin,face,carcinoma,NS c.532C>A p.H178N 17:7675080-7675080 0
22 COSM10654 TP53 skin,face,carcinoma,NS c.637C>T p.R213* 17:7674894-7674894 0
23 COSM6903965 TP53 skin,ear,carcinoma,squamous cell carcinoma c.988C>T p.L330F 17:7673540-7673540 0
24 COSM45114 TP53 skin,ear,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 0
25 COSM44832 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 0
26 COSM45830 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 0
27 COSM10812 TP53 skin,face,carcinoma,NS c.722C>T p.S241F 17:7674241-7674241 0
28 COSM10726 TP53 skin,face,carcinoma,NS c.856G>A p.E286K 17:7673764-7673764 0
29 COSM10992 TP53 skin,face,carcinoma,NS c.844C>G p.R282G 17:7673776-7673776 0
30 COSM45304 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 0
31 COSM10788 TP53 skin,ear,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 0
32 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 0
33 COSM10886 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 0
34 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 0
35 COSM11073 TP53 skin,face,carcinoma,NS c.1024C>T p.R342* 17:7670685-7670685 0
36 COSM43582 TP53 skin,face,carcinoma,NS c.454C>T p.P152S 17:7675158-7675158 0
37 COSM45733 TP53 skin,face,carcinoma,NS c.432G>A p.Q144Q 17:7675180-7675180 0
38 COSM10704 TP53 skin,face,carcinoma,NS c.844C>T p.R282W 17:7673776-7673776 0
39 COSM12296 TP53 skin,lip,carcinoma,NS c.292C>T p.P98S 17:7676077-7676077 0
40 COSM43700 TP53 skin,face,carcinoma,NS c.712T>A p.C238S 17:7674251-7674251 0
41 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
42 COSM10794 TP53 skin,ear,carcinoma,squamous cell carcinoma c.796G>A p.G266R 17:7673824-7673824 0
43 COSM44227 TP53 skin,face,carcinoma,NS c.854A>T p.E285V 17:7673766-7673766 0
44 COSM10768 TP53 skin,face,carcinoma,NS c.535C>T p.H179Y 17:7675077-7675077 0
45 COSM43651 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 0
46 COSM44435 TP53 skin,face,carcinoma,NS c.96+1G>A p.? 17:7676381-7676381 0
47 COSM43920 TP53 skin,face,carcinoma,NS c.680C>T p.S227F 17:7674283-7674283 0
48 COSM43753 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 0
49 COSM44436 TP53 skin,face,carcinoma,NS c.375+2T>C p.? 17:7675992-7675992 0
50 COSM43596 TP53 skin,face,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 0

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
50 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.48 BRAF HRAS TP53
2 11.36 BRAF HRAS TP53
3 11 BRAF HRAS TP53
4 9.88 HOTAIR TP53 UCA1

GO Terms for Squamous Cell Carcinoma

Sources for Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....